Treatment of hyperprolactinaemia with metergoline for periods up to 5 years: clinical and biological tolerability.

Abstract

Forty patients with hyperprolactinaemia were treated with metergoline (8 to 12 mg/day) for periods up to 5 years. Analysis of the results of clinical and biological tolerability showed that treatment was generally well tolerated and although 28 patients complained of drug-related side-effects of various kinds, principally nausea, these were usually mild, present at the beginning of treatment and disappeared spontaneously in spite of continued metergoline administration over a prolonged period. No patient stopped treatment because of side-effects. Laboratory parameters also stayed within normal levels and there was no evidence of any alterations in the ECG. It is concluded, therefore, that metergoline is a well-tolerated as well as an effective ergolinic compound for use in those patients in whom prolonged treatment with a prolactin-lowering drug is considered necessary.

• Authors: L Falsetti, A M Voltolini, M Schimberni, A E Pontiroli
• Journal: Current medical research and opinion (Curr Med Res Opin) Vol. 8 Issue 5 Pg. 327-32 ( 1983) ISSN: 0300-7995 [Print] England
• PMID: 6839798 (Publication Type: Journal Article)

Chemical References

• Ergolines
• Metergoline
• Prolactin

Topics

• Adenoma (metabolism)
• Adult
• Drug Tolerance
• Ergolines (adverse effects)
• Female
• Humans
• Metergoline (adverse effects)
• Pituitary Neoplasms (metabolism)
• Prolactin (blood, metabolism)
• Retroperitoneal Fibrosis (chemically induced)
• Time Factors